Fig. 4: Pretreatment tumor T cell infiltrates and responses to CAR-T therapy.

a, Distribution of tumors with high, intermediate or negative/low CD3 infiltrates in pretreatment tumors from patients evaluable for survival (n = 57). b,c, Survival comparison of all evaluable rHGG (b) or rGBM (c) patients with either negative/low (1, 2) or intermediate/high (3, 4) tumor CD3 IHC scores. Dashed lines depict medians in months (Mo). Median survival times with 95% CIs in parentheses are also indicated; NA means infinity. P values comparing survival distribution of each group using the two-sided peto–peto test are depicted. d,e, MRI images from CD3 high UPN265 (d) and CD3 intermediate UPN301 (e). Ticks in timelines indicate 6-month intervals; SOC, standard of care involving surgery, radiation and temozolomide; PCV, procarabaxine, CCNU and vincristine; Bev., bevacizumab; CCNU, lomustine; SAP, survival after progression. f, Linear regression model of log survival time for survival evaluable rGBM patients (n = 41) showing estimates of the survival effect for CD3 intermediate/high (3, 4), Tn/mem product (arm 5) or both. Parameters were compared to a CD3 low/negative (1, 2) and Tcm (arms 1–4) patient reference group. Point estimates of the effect of each variable, or both, are depicted as a multiplicative factor (center dot, with 95% CIs as horizonal lines) that is applied to survival time; 95% CI horizontal lines do not cross vertical dashed line, demonstrating P < 0.05 for each effect; reference Methods for statistical analysis details.